Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.025 4.1% 0.635 13,162,820 16:23:02
Bid Price Offer Price High Price Low Price Open Price
0.63 0.64 0.635 0.61 0.61
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.03 -7.66 -0.60 45
Last Trade Time Trade Type Trade Size Trade Price Currency
17:05:47 O 250,000 0.635 GBX

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Investors    Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
15/6/202115:55Tissue Regenix delivering practical solutions to real clinical issues6,622
26/5/202013:31Torex with Charts & News14
15/1/202007:09TOREX 2007 - THE TILLS RING AT LAST13
14/1/202020:51Terrane Minerals- Cu explorer, trading in Canada17
12/11/201915:05Fair Value ?4

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

Tissue Regenix Daily Update: Tissue Regenix Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 0.61p.
Tissue Regenix Group Plc has a 4 week average price of 0.59p and a 12 week average price of 0.55p.
The 1 year high share price is 0.92p while the 1 year low share price is currently 0.30p.
There are currently 7,033,077,499 shares in issue and the average daily traded volume is 9,042,140 shares. The market capitalisation of Tissue Regenix Group Plc is £44,660,042.12.
channel pirate: Just looked back to last year and the Results for year ending December 2019 were announced on the 5th June 2020. 2nd September 2020, Interim Results were announced Next three months could not only be interesting, but share price moving as well Still got those fingers crossed Guys
david gruen: "I really don't get this share, there is no reason to go down now." There is one very good reason to take down the share price Doing so will flush out weak holders and transfer their shares to larger players. Notice the low volume on down days. There's no supply in the market. This time next year we'll be trading at 5 x the current market cap in my opinion.
rocketblast: TRX breaking news is expected this week or next as Qtr 2 end nears. Maybe transformative for TRX. We will see a jump above 1p as markets realise TRX have a great future. The current valuation is very cheap and worth a TopUp in my view. AGM was positive as we head into a very bright future with strong products and deals in the pipeline.
rocketblast: As soon as deals are signed we will have blastoff...Remind you all..... Gervais Williams of Premier Miton discusses (Vox Markets) his investments like TRX he sees as most undervalued and a great opportunity. He talks about the flywheel effect and great potential in TRX as healthcare market opens up.
mk_advfn: I see the share price in the next 6 mothns to be double from what it is today.
contact2fsnetcouk: Disappointed by the downward share price movement. Another share of mine [SUN] which is involved in (stalled) elective surgery is progressing much better.
channel pirate: Due to the extra capacity which we are expecting to come "on stream" in H2 this year, I'm expecting Tissue Regenix share price to be gaining momentum as the year progresses. Therefore I have been re-positioning my TRX portfolio by selling in my ordinary share account and buying back in the ISA account. Albeit I seem to have have ended up with extra shares, which has also allowed me to reduce my break even price. Being a long term holder here I have had to work hard to reduce my original break even of over 20p five years ago. Good Luck to all.
ultrasilva: My average is 0.63. I bought early February with the aim to hold long term and was expecting the share price to only start going up 2H 2021, and more from 2022 when things go back to 'new normal' covid-wise and elective surgeries pick up. Also TRX said they were still on track to complete the 2 new rooms in 1H 2021, unless I misread things? So in some sense being where we are now is not surprising - it was more surprising to see it go close to 0.9 earlier this year... right?
lazygun: Gareth Jones did a great job in overseeing that massively diluted fund raise last year. Trx are doing better than I expected in starting to recover from that debacle. It’s entirely possible if they are starting to see continued upticks in business this year, for them to double from here. Was reading back their trading update, and overall seems quite positive. Demand seems to be there for their products, with covid being the main factor in holding them back. Assuming the vaccination programs globally demonstrate their effectiveness, we may see a faster recover in tissue’s share price than I had previously expected. Think they also need to do a share consolidation - 7 billion shares is too many.... L.
enteleon: Chinadog3- Thank you for your compliment. I don't have any special(and certainly not insider) information about TRX. I have followed TRX for a while and nearly all my investments are in the medical/pharma/biotech space as these tend to be relatively defensive. I have a medical/surgical background. Ali47fish- I hope the below helps to put the Company circumstances into perspective. Please do correct me where necessary. TRX has been horribly hit by a combination of both Woodford and Invesco selling down in the second half of 2019. Woodford, as most of you know, was the former star of Invesco and Invesco tended to follow Woodford in the last few years. When things went badly wrong for Woodford, Invesco copied his selling. Additionally, TRX has been plagued by some very erratic management moves in the last 15 months, with several Finance Directors coming and going. The loan deal with MIDCAP was announced in November, 2019, but clearly met with major infighting within the Board. The then FD left almost immediately. The loan was at an interest rate of approx 6.7% plus LIBOR, which would have given a rate of close to 10% p.a. TRX borrowed approx $7.5M, but returned $5.5M in a major revision to the loan earlier this year. At present, I believe that TRX's total debt is $2M and this is to MIDCAP. The acquisitions that TRX has made in the past have been financed through share cash-calls, hence the large number of shares in issue (1,171,971,322). Woodford and Invesco were very supportive of these cash-calls. Returning the $5.5M to MIDCAP has left TRX with a cash-flow crisis with cash running out by the end of the second week in May. To address this, TRX has to raise debt, sell off the whole or part of the Company or hold a cash-call, the last of which would dilute all investors' holdings. Purely as my opinion, I do believe that the appointment of Jonathan Glenn to Chairman/CEO may be crucial. Glenn has been a non-exec director of TRX since Jan 2016. He made his name by steering Consort Medical (was CSRT) to a very successful buyout by the Swedish Recipharm Group, finalised in February this year at an enterprise value in excess of £500M. Glenn is a chartered accountant by profession, so is commercially savvy and knows TRX inside-out as well as having long experience in the medical appliance world (appointed CEO of Consort December, 2007). So, in summary, and this is purely my opinion: Erratic previous management, Woodford/Invesco divestment (there is still the 19.98% share overhang with Link) and perhaps some over-reach in acquisitions have left TRX asset-rich, but cash poor. Their products appear to be in considerable demand and have FDA approval- indeed one of the problems has been a supply-side crisis, not demand-side. TRX is now a commercial operation, not a research outfit. It needs serious commercial talent to pull the Company through what should be a short-term funding crisis. The Covid-19 pandemic has added additional stress, of course. To me, TRX is priced as if it was a small pharma/biotech company waiting for interminable FDA/CE approvals on a long-haul research basis. That is just not the case. Please, please correct and criticise; we are all here to learn. Wishing all long-holders the very best of luck.
Tissue Regenix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 19:31:07